Description
Voglibose Tablets
Healthy Inc is a specialized global supplier and exporter of advanced endocrinology, metabolic, and glycemic control therapeutics. We provide ultra-high-precision, micro-dosed Voglibose Tablets (0.2 mg / 0.3 mg), manufactured in WHO–GMP certified, high-capacity oral solid dosage facilities. This “Post-Prandial Glucose Regulator” is a massive-volume, essential export to diabetic care centers, primary care networks, retail pharmacy distributors, and government health ministries in LATAM, the Middle East, Africa, and Southeast Asia, serving as a highly targeted, first-line or adjunctive intervention for Type 2 Diabetes Mellitus driven by severe mealtime sugar spikes.
Product Overview
This formulation contains Voglibose, a highly potent and reversible competitive inhibitor of the alpha-glucosidase enzymes located in the brush border of the small intestine.
The “Carbohydrate Blocker & Post-Prandial” Specialist:
- Mechanism (Enzymatic Delay): When a patient consumes a carbohydrate-heavy meal (like rice, bread, or pasta), intestinal enzymes must break those complex starches down into simple glucose before the body can absorb them. Voglibose binds to these enzymes, drastically slowing down this digestive process. Instead of a massive, dangerous rush of glucose hitting the bloodstream all at once, the absorption is delayed and spread out smoothly over several hours.
- The Asian & Middle Eastern Diet Champion: In export markets where standard diets are heavily reliant on high-glycemic-index carbohydrates, fasting blood sugar is often normal, but post-meal (post-prandial) spikes are dangerously high. Voglibose specifically targets and flattens this exact physiological spike without stimulating the pancreas to produce more insulin.
- Beta-Cell Preservation: By flattening the post-meal glucose peak, Voglibose reduces the immediate, severe workload on the pancreatic beta-cells (the cells that produce insulin), helping to preserve their function and slow the overall progression of the diabetic disease state.
Product Composition & Strength
We supply this product as a highly precise Uncoated or Film-Coated Tablet, packed strictly in high-barrier Alu-Alu blister strips. Alu-Alu packaging is completely non-negotiable, as Voglibose is intensely sensitive to moisture degradation.
| Active Ingredient | Strength | Primary Clinical Use |
|---|---|---|
| Voglibose USP/BP/JP | 0.2 mg | Standard Adult Dose for initiation of therapy and mild post-prandial spikes. |
| Voglibose USP/BP/JP | 0.3 mg | Maintenance therapy for severe post-meal hyperglycemia and high-carbohydrate diets. |
| Excipients | Microcrystalline Cellulose / Lactose / Magnesium Stearate | Diluent / Lubricant (Engineered for immediate gastric dissolution) |
*Pack Sizes: 10×10 or 10×15 Alu-Alu Blisters (Optimized for frequent, meal-time dispensing regimens).
Technical & Logistics Specifications
Critical data for Pharmaceutical Importers, Endocrinology Distributors, and Diabetic Clinics.
| HS Code | 3004.90.99 (Medicaments containing other active substances – Antidiabetics) |
| CAS Number | 83480-29-9 |
| Dosage Form | Tablet (Immediate Release) |
| Packaging | High-Barrier Alu-Alu Blisters (CRITICAL). Voglibose is highly susceptible to hydrolysis. Strict moisture barriers are mandatory to prevent loss of clinical efficacy. |
| Storage | Store strictly below 30°C in a dry place. Protect from Light and Moisture. |
| Certificates | WHO-GMP, COPP, Free Sale Certificate |
Manufacturing Authority
Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.
- Micro-Dose Geometric Blending Validation: Because the active ingredient is dosed in fractions of a single milligram (0.2mg), uneven mixing can result in tablets with zero API and tablets with dangerously toxic amounts. Our facilities utilize advanced high-shear homogenizers and rigorous geometric dilution protocols, verified by HPLC assay testing, to guarantee absolute, flawless dose uniformity across millions of units.
- Rapid Dissolution Profiling: To be effective, the tablet must completely dissolve and bathe the intestinal enzymes *before* the food arrives. Rigorous multi-stage dissolution testing ensures immediate, predictable release within the upper gastrointestinal tract.
Therapeutic Indications (Human Use)
Indicated for the comprehensive management of complex metabolic disorders:
- Type 2 Diabetes Mellitus (T2DM): Improvement of post-prandial hyperglycemia in patients whose blood sugar levels are inadequately controlled by diet and exercise alone, or when used concurrently with other oral hypoglycemic agents or insulin preparations.
Dosage & Administration
Recommended Dosage (Strictly as per Endocrinologist/Physician):
- Standard Adult Dosing: Typically 0.2 mg to 0.3 mg taken three times a day (TID), corresponding to the three main meals.
- Administration (THE “FIRST BITE” RULE IS CRITICAL): To be effective, Voglibose must be present in the intestine alongside the carbohydrates. These tablets MUST be taken immediately before or with the very first bite of a main meal. If the patient forgets and takes the tablet after eating, the medication will have zero therapeutic effect.
Safety Warnings (CRITICAL):
- Gastrointestinal Distress (Flatulence/Diarrhea): Because Voglibose stops carbohydrates from being absorbed in the small intestine, those complex sugars ferment in the large intestine. This almost universally causes severe flatulence, bloating, borborygmus (stomach rumbling), and loose stools during the first few weeks of therapy. Patients must be counseled that this is a sign the drug is working and usually subsides over time.
- Hypoglycemia Protocol (CRITICAL RESCUE WARNING): While Voglibose monotherapy rarely causes low blood sugar, it is often prescribed with insulin or sulfonylureas. If severe hypoglycemia occurs, the patient MUST be treated with pure Dextrose (Glucose) powder or tablets. They cannot be treated with table sugar (sucrose), candy, or complex carbs, because the Voglibose will physically block the body from absorbing it in time to save their life.
- Hepatic Impairment: Rarely associated with severe hepatic dysfunction and jaundice. Regular monitoring of liver function tests (LFTs) is recommended.
Global Export & Contract Manufacturing Services
Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Endocrinology Formulations, allowing brands to launch high-quality generic medicines under their essential label. Whether you are looking for a reliable Retail Pharmacy Supplier for diabetic care programs in Southeast Asia or a B2B Pharma Marketplace partner for the Middle East, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.










Reviews
There are no reviews yet.